PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer

Several poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors are now in clinical use for tumours with defects in BReast CAncer genes BRCA1 or BRCA2 that result in deficient homologous recombination repair (HRR). Use of olaparib, niraparib or rucaparib for the treatment of high-grade sero...

Descripción completa

Detalles Bibliográficos
Autores principales: Dickson, Kristie-Ann, Xie, Tao, Evenhuis, Christian, Ma, Yue, Marsh, Deborah J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395221/
https://www.ncbi.nlm.nih.gov/pubmed/34445211
http://dx.doi.org/10.3390/ijms22168506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395221/
https://www.ncbi.nlm.nih.gov/pubmed/34445211
http://dx.doi.org/10.3390/ijms22168506

Ejemplares similares